Limits...
New pharmacologic perspectives in pneumology: beclomethasone-formoterol extrafine.

Paggiaro P - Open Respir Med J (2009)

Bottom Line: Combination therapy with inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) is recommended in a large part of asthmatic subjects (those who are not controlled with low-dose ICS alone).Recently, a new beclomethasone/formoterol combination in an extrafine HFA formulation has been developed.This new technology allows to obtain a very high fine particle fraction which reaches lower airways, while the dose which remain in the upper airways and possibly responsible for systemic side effects is very low.Therefore, this combination allows a different dose ratio between BDP and the other ICS (budesonide, fluticasone), in favour of a lower dose of BDP.

View Article: PubMed Central - PubMed

Affiliation: Cardio-Thoracic and Vascular Department, University of Pisa, Italy.

ABSTRACT
International asthma guidelines have recently focused on the concept of , which is the main outcome to reach and maintain in the long term management. Asthma control is associated with several positive consequences, both in terms of quality of life and pathophysiological findings. Combination therapy with inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) is recommended in a large part of asthmatic subjects (those who are not controlled with low-dose ICS alone).Recently, a new beclomethasone/formoterol combination in an extrafine HFA formulation has been developed. This new technology allows to obtain a very high fine particle fraction which reaches lower airways, while the dose which remain in the upper airways and possibly responsible for systemic side effects is very low. Therefore, this combination allows a different dose ratio between BDP and the other ICS (budesonide, fluticasone), in favour of a lower dose of BDP. Recent studies have demonstrated the equivalence of this new combination with the other ICS/LABA combination, as regards all asthma outcomes. Then, this new BDP/formoterol combination may increase the possibility to manage adequately patients with moderate-to-severe asthma.

No MeSH data available.


Related in: MedlinePlus

Definition of the different levels of asthma control according to International GINA Guidelines [2].
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2682924&req=5

Figure 1: Definition of the different levels of asthma control according to International GINA Guidelines [2].

Mentions: The control of asthma is defined according to the criteria reported in Fig. (1). With an integrated evaluation of symptoms, use of rescue medication, level of pulmonary function, and rate of exacerbations, the control of the disease can be evaluated in a fairly easy way. The assessment of the control is necessary for the decision about the asthma management: the lack of control requires immediately a change in the level of pharmacologic treatment and a revision of the management plan, while a good control lead to consider the persistence or the step-down in the level of asthma treatment. This method of the evaluation of the control is simple and easily performed by the patient and the doctor, and this may improve the global management of the disease.


New pharmacologic perspectives in pneumology: beclomethasone-formoterol extrafine.

Paggiaro P - Open Respir Med J (2009)

Definition of the different levels of asthma control according to International GINA Guidelines [2].
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2682924&req=5

Figure 1: Definition of the different levels of asthma control according to International GINA Guidelines [2].
Mentions: The control of asthma is defined according to the criteria reported in Fig. (1). With an integrated evaluation of symptoms, use of rescue medication, level of pulmonary function, and rate of exacerbations, the control of the disease can be evaluated in a fairly easy way. The assessment of the control is necessary for the decision about the asthma management: the lack of control requires immediately a change in the level of pharmacologic treatment and a revision of the management plan, while a good control lead to consider the persistence or the step-down in the level of asthma treatment. This method of the evaluation of the control is simple and easily performed by the patient and the doctor, and this may improve the global management of the disease.

Bottom Line: Combination therapy with inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) is recommended in a large part of asthmatic subjects (those who are not controlled with low-dose ICS alone).Recently, a new beclomethasone/formoterol combination in an extrafine HFA formulation has been developed.This new technology allows to obtain a very high fine particle fraction which reaches lower airways, while the dose which remain in the upper airways and possibly responsible for systemic side effects is very low.Therefore, this combination allows a different dose ratio between BDP and the other ICS (budesonide, fluticasone), in favour of a lower dose of BDP.

View Article: PubMed Central - PubMed

Affiliation: Cardio-Thoracic and Vascular Department, University of Pisa, Italy.

ABSTRACT
International asthma guidelines have recently focused on the concept of , which is the main outcome to reach and maintain in the long term management. Asthma control is associated with several positive consequences, both in terms of quality of life and pathophysiological findings. Combination therapy with inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) is recommended in a large part of asthmatic subjects (those who are not controlled with low-dose ICS alone).Recently, a new beclomethasone/formoterol combination in an extrafine HFA formulation has been developed. This new technology allows to obtain a very high fine particle fraction which reaches lower airways, while the dose which remain in the upper airways and possibly responsible for systemic side effects is very low. Therefore, this combination allows a different dose ratio between BDP and the other ICS (budesonide, fluticasone), in favour of a lower dose of BDP. Recent studies have demonstrated the equivalence of this new combination with the other ICS/LABA combination, as regards all asthma outcomes. Then, this new BDP/formoterol combination may increase the possibility to manage adequately patients with moderate-to-severe asthma.

No MeSH data available.


Related in: MedlinePlus